Alpha 2.0

» Articles » PMID: 39678683

Prediction Value of High Serum Pentraxin-3 for Short-Term Recurrence of Cerebral Infarction in Patients Accompanied with Intracranial Atherosclerotic Stenosis Within One Year

Overview

Overview

Journal Int J Gen Med

Publisher Dove Medical Press

Specialty General Medicine

Date 2024 Dec 16

PMID 39678683

Authors

Authors

Zhiyong Cao

Zhenhua Chen

Jiawei Yang

Xiaozhu Shen

Chen Chen

Xiangyang Zhu

Qi Fang

Affiliations

Affiliations

Soon will be listed here.

Abstract

Objective: Elevated serum pentraxin-3 levels are generally considered a risk factor for atherosclerosis. However, there is limited data on the relationship between pentraxin-3 and cerebral infarction (CI) accompanied by intracranial atherosclerotic stenosis (ICAS). This study aims to investigate the association between pentraxin-3 (PTX-3) and short-term recurrence in cerebral infarction caused by ICAS patients within one year.

Methods: A prospective observational study was conducted. Cerebral infarction accompanied by intracranial atherosclerotic stenosis (CI-ICAS) patients were selected from January 2020 to December 2023. Recurrent ischemic stroke (RIS) is defined as a new neurological deficit that appears after a period of clinical stabilization, lasting more than 24 hours, with an attributable new ischemic lesion that can be confirmed by CT or MRI. Serum pentraxin-3 levels were determined on admission. Multivariate logistic regression analysis was used to investigate the relationship between serum pentraxin-3 and RIS.

Results: Among 398 patients enrolled, 112 cases (28.1%) had recurrence within one year. The elevation of serum PTX-3 level in patients accompanied with ICAS was independently correlated with recurrent stroke. Therefore, it is worth considering the possibility of intervening in higher PTX-3 levels. Serum pentraxin-3 was significantly higher in patients with RIS (15.16 vs 10.21 µmol/L, <0.001). Correlation analysis showed that PTX-3 was correlated with age, LDL, Hs-CRP, Baseline NIHSS score, and Hcy ( < 0.001). Univariate logistic regression analysis showed that pentraxin-3 remained an independent predictor of recurrent ischemic stroke after adjusting for major confounding factors (OR = 1.21, 95% CI: 1.06-1.39, = 0.007).

Conclusion: The elevation of serum pentraxin-3 level in patients with ischemic stroke was independently correlated with the recurrence of stroke within one year. Therefore, intervention in serum pentraxin-3 levels may be worth considering.

References

1.

Xue J, Xiang Y, Jiang X, Jin A, Hao X, Li K . The joint association of lipoprotein(a) and lipoprotein-associated phopholipase A2 with the risk of stroke recurrence. J Clin Lipidol. 2024; 18(5):e729-e737. DOI: 10.1016/j.jacl.2024.04.133. View

2.

Shindo A, Maki T, Mandeville E, Liang A, Egawa N, Itoh K . Astrocyte-Derived Pentraxin 3 Supports Blood-Brain Barrier Integrity Under Acute Phase of Stroke. Stroke. 2016; 47(4):1094-100. PMC: 4811738. DOI: 10.1161/STROKEAHA.115.012133. View

3.

Hankey G, Wee C . Predicting Early Recurrent Stroke With the Recurrence Risk Estimator. JAMA Neurol. 2016; 73(4):376-8. DOI: 10.1001/jamaneurol.2015.5047. View

4.

Savchenko A, Imamura M, Ohashi R, Jiang S, Kawasaki T, Hasegawa G . Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol. 2008; 215(1):48-55. DOI: 10.1002/path.2314. View

5.

Ye X, Wang Z, Lei W, Shen M, Tang J, Xu X . Pentraxin 3: A promising therapeutic target for cardiovascular diseases. Ageing Res Rev. 2023; 93:102163. DOI: 10.1016/j.arr.2023.102163. View

6.

Eriksson M, Grundberg A, Inge E, von Euler M . Stroke Recurrence Following 28 Days After First Stroke in Men and Women 2012 to 2020: Observations From the Swedish Stroke Register. J Am Heart Assoc. 2023; 12(3):e028222. PMC: 9973638. DOI: 10.1161/JAHA.122.028222. View

7.

Rajkovic I, Wong R, Lemarchand E, Rivers-Auty J, Rajkovic O, Garlanda C . Pentraxin 3 promotes long-term cerebral blood flow recovery, angiogenesis, and neuronal survival after stroke. J Mol Med (Berl). 2018; 96(12):1319-1332. PMC: 6245246. DOI: 10.1007/s00109-018-1698-6. View

8.

Gutierrez J, Turan T, Hoh B, Chimowitz M . Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment. Lancet Neurol. 2022; 21(4):355-368. DOI: 10.1016/S1474-4422(21)00376-8. View

9.

Wang Y, Meng R, Liu G, Cao C, Chen F, Jin K . Intracranial atherosclerotic disease. Neurobiol Dis. 2018; 124:118-132. PMC: 6363839. DOI: 10.1016/j.nbd.2018.11.008. View

10.

Saini V, Guada L, Yavagal D . Global Epidemiology of Stroke and Access to Acute Ischemic Stroke Interventions. Neurology. 2021; 97(20 Suppl 2):S6-S16. DOI: 10.1212/WNL.0000000000012781. View

11.

Liebeskind D, Prabhakaran S, Azhar N, Feldmann E, Campo-Bustillo I, Sangha R . Mechanisms of early Recurrence in Intracranial Atherosclerotic Disease (MyRIAD): Rationale and design. J Stroke Cerebrovasc Dis. 2020; 29(10):105051. PMC: 7490766. DOI: 10.1016/j.jstrokecerebrovasdis.2020.105051. View

12.

Zietz A, Gorey S, Kelly P, Katan M, McCabe J . Targeting inflammation to reduce recurrent stroke. Int J Stroke. 2023; 19(4):379-387. PMC: 10964390. DOI: 10.1177/17474930231207777. View

13.

Anniwaer J, Liu M, Xue K, Maimaiti A, Xiamixiding A . Homocysteine might increase the risk of recurrence in patients presenting with primary cerebral infarction. Int J Neurosci. 2018; 129(7):654-659. DOI: 10.1080/00207454.2018.1517762. View

14.

Ballout A, Liebeskind D . Recurrent stroke risk in intracranial atherosclerotic disease. Front Neurol. 2022; 13:1001609. PMC: 9475064. DOI: 10.3389/fneur.2022.1001609. View

15.

de Oliveira T, Souza D, Teixeira M, Amaral F . Tissue Dependent Role of PTX3 During Ischemia-Reperfusion Injury. Front Immunol. 2019; 10:1461. PMC: 6635462. DOI: 10.3389/fimmu.2019.01461. View

16.

Park J, Ovbiagele B . Neurologic symptom severity after a recent noncardioembolic stroke and recurrent vascular risk. J Stroke Cerebrovasc Dis. 2015; 24(5):1032-7. PMC: 4408262. DOI: 10.1016/j.jstrokecerebrovasdis.2014.12.033. View

17.

Ninomiya I, Kanazawa M, Uemura M, Onodera O . Elevated serum pentraxin 3 levels might predict the diagnosis of branch atheromatous disease at a very early stage. Eur J Neurol. 2020; 27(7):1279-1284. DOI: 10.1111/ene.14249. View

18.

Flach C, Muruet W, Wolfe C, Bhalla A, Douiri A . Risk and Secondary Prevention of Stroke Recurrence: A Population-Base Cohort Study. Stroke. 2020; 51(8):2435-2444. PMC: 7382537. DOI: 10.1161/STROKEAHA.120.028992. View

19.

Zhang Y, Hu H, Liu C, Wu J, Zhou S, Zhao T . Serum pentraxin 3 as a biomarker for prognosis of acute minor stroke due to large artery atherosclerosis. Brain Behav. 2020; 11(1):e01956. PMC: 7821624. DOI: 10.1002/brb3.1956. View

20.

Tsivgoulis G, Safouris A, Kim D, Alexandrov A . Recent Advances in Primary and Secondary Prevention of Atherosclerotic Stroke. J Stroke. 2018; 20(2):145-166. PMC: 6007302. DOI: 10.5853/jos.2018.00773. View